Advicenne Future Growth

Future criteria checks 6/6

Advicenne is forecast to grow earnings and revenue by 47.3% and 31.8% per annum respectively. EPS is expected to grow by 54.5% per annum. Return on equity is forecast to be 62.8% in 3 years.

Key information

47.3%

Earnings growth rate

54.5%

EPS growth rate

Pharmaceuticals earnings growth	21.3%
Revenue growth rate	31.8%
Future return on equity	62.8%
Analyst coverage	Low
Last updated	15 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:3MM - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	8	-4	-6	-4	2
12/31/2025	5	9	9	9	2
12/31/2024	4	-9	-7	-6	2
6/30/2024	3	-9	-6	-5	N/A
3/31/2024	3	-8	-6	-5	N/A
12/31/2023	3	-7	-7	-6	N/A
9/30/2023	3	-9	-8	-7	N/A
6/30/2023	3	-10	-8	-8	N/A
3/31/2023	3	-11	-9	-8	N/A
12/31/2022	3	-11	-9	-9	N/A
9/30/2022	3	-10	-9	-9	N/A
6/30/2022	4	-9	-9	-9	N/A
3/31/2022	4	-11	-11	-11	N/A
12/31/2021	4	-12	-13	-13	N/A
9/30/2021	4	-14	-13	-13	N/A
6/30/2021	4	-15	-15	-14	N/A
3/31/2021	4	-15	-14	-13	N/A
12/31/2020	3	-15	-12	-12	N/A
9/30/2020	3	-15	-13	-12	N/A
6/30/2020	3	-15	N/A	N/A	N/A
3/31/2020	2	-14	N/A	N/A	N/A
12/31/2019	3	-14	-10	-9	N/A
9/30/2019	2	-11	N/A	N/A	N/A
6/30/2019	2	-8	-11	-11	N/A
3/31/2019	1	-6	-11	-10	N/A
12/31/2018	1	-5	-10	-10	N/A
9/30/2018	2	-6	N/A	N/A	N/A
6/30/2018	2	-7	-7	-6	N/A
3/31/2018	2	-7	N/A	-6	N/A
12/31/2017	3	-6	N/A	-6	N/A
9/30/2017	2	-5	N/A	-5	N/A
6/30/2017	2	-4	N/A	-5	N/A
3/31/2017	2	-4	N/A	-3	N/A
12/31/2016	2	-4	N/A	0	N/A
12/31/2015	3	-2	N/A	N/A	N/A
12/31/2014	2	-2	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3MM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: 3MM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 3MM is expected to become profitable in the next 3 years.

Revenue vs Market: 3MM's revenue (31.8% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 3MM's revenue (31.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 3MM's Return on Equity is forecast to be very high in 3 years time (62.8%).

Advicenne Future Growth

Future criteria checks 6/6

Key information

Recent future growth updates

Forecast to breakeven in 2023

Recent updates

Advicenne S.A. to Report First Half, 2025 Results on Sep 18, 2025

Less than half of directors are independent

Advicenne Achieves Major Milestones in the US Due to Several Positive FDA Opinion on ADV7103

Full year 2023 earnings released: €0.67 loss per share (vs €1.16 loss in FY 2022)

New minor risk - Financial data availability

Less than half of directors are independent

Less than half of directors are independent

Advicenne S.A. to Report First Half, 2024 Results on Sep 18, 2024

Advicenne S.A. to Report Fiscal Year 2022 Results on Mar 30, 2023

Advicenne Updates on Availability of Sibnayal to Patients and Caregivers in Great Britain

Advicenne Announces Commercial Launch of Sibnayal in Great Britain

Advicenne S.A. Announces Executive Changes

Advicenne Appoints Philippe Boucheron as Chairman of Its Board of Directors

Advicenne Announces the Release of Results of a Study Showing Improved Quality of Life in Patients Living With DRTa and Treated by ADV7103

Advicenne Ordinary Shareholders' Meeting Approves Delisting from Regulated Market of Euronext Brussels

Forecast to breakeven in 2023

Advicenne Announces Positive Opinion from the French Transparency Commission (HAS) for Its Drug Sibnayal™ in dRTA

First half 2021 earnings released: €0.93 loss per share (vs €0.92 loss in 1H 2020)

Advicenne Receives Medicines and Healthcare products Regulatory Agency Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA

Advicenne S.A. announced that it has received €9.42128 million in funding

Chief Executive Officer Peter Meeus has left the company

Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Changes to support Commercialisation

Advicenne Expects Imminent Marketing Authorization for ADV7103 (Sibnayal™) for dRTA in Europe

Advicenne S.A. Provides an Update as its Operations Evolve

New 90-day high: €12.10

New 90-day high: €11.70

Advicenne Appoints Peter Meeus as Chief Executive Officer, Effective February 15, 2021

Advicenne Receives Positive CHMP Opinion Recommending Approval of ADV7103 (sibnayal) for the Treatment of Distal Renal Tubular Acidosis (dRTA)

New 90-day high: €8.46

New 90-day high: €7.58

New 90-day low: €5.96

New 90-day low: €6.46

First half earnings released

New 90-day low - €6.64

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies